GPAM

Across TCGA pan-cancer cohorts, GPAM Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GPAM data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher GPAM Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPAM expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ACC, COAD, and UCEC are the cancer types where GPAM Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.145	0.888	<.001	45	view →
COAD	OS	Median	All	0.168	0.806	.002	12	view →
UCEC	DFS	Median	All	0.945	0.619	.006	10	view →
PRAD	DFS	Median	All	0.111	0.886	<.001	8	view →
SKCM	DFS	Median	All	1.000	0.719	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GPAM–ACC (OS)

Open the ACC breakdown →